Mortality benefit with antifibrotics in idiopathic pulmonary fibrosis: real world evidence or bias?

被引：6
|
作者：
Suissa, Samy [1 ,2 ,3 ]
Assayag, Deborah [1 ,3 ,4 ]
机构：
[1] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada
[2] Jewish Gen Hosp, Lady Davis Inst, Ctr Clin Epidemiol, Montreal, PQ, Canada
[3] McGill Univ, Dept Med, Montreal, PQ, Canada
[4] McGill Univ, Hlth Ctr, Div Resp Med, Montreal, PQ, Canada
来源：
EUROPEAN RESPIRATORY JOURNAL | 2021年 / 57卷 / 03期
关键词：
IMMORTAL TIME BIAS;
D O I：
10.1183/13993003.04562-2020
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Mortality outcomes in patients with idiopathic pulmonary fibrosis treated with antifibrotics: a real world study
    Barnes, Joshua
    Harris, Emma
    Matos, Luis
    Harding, Katie
    Thillai, Muhunthan
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [2] Antifibrotics and Reduced Mortality in Idiopathic Pulmonary Fibrosis: Immortal Time Bias
    Suissa, Samy
    Suissa, Karine
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207 (01) : 105 - 109
  • [3] Antifibrotics and mortality in idiopathic pulmonary fibrosis: external validity and avoidance of immortal time bias
    Hozumi, Hironao
    Miyashita, Koichi
    Nakatani, Eiji
    Inoue, Yusuke
    Yasui, Hideki
    Suzuki, Yuzo
    Karayama, Masato
    Furuhashi, Kazuki
    Enomoto, Noriyuki
    Fujisawa, Tomoyuki
    Inui, Naoki
    Suda, Takafumi
    RESPIRATORY RESEARCH, 2024, 25 (01)
  • [4] ANTIFIBROTICS FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS IN THE REAL WORLD: A SINGLE CENTRE EXPERIENCE
    Santos, C.
    Woods, A.
    Jo, H.
    Jee, A.
    Webster, S.
    Corte, T.
    RESPIROLOGY, 2018, 23 : 124 - 124
  • [5] Real-world cohort evaluation of the impact of the antifibrotics in patients with idiopathic pulmonary fibrosis
    Dempsey, Timothy M.
    Thao, Viengneesee
    Helfinstine, David A.
    Chang, Yu-Hui H.
    Sangaralingham, Lindsey
    Limper, Andrew H.
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62 (04)
  • [6] Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis
    Wright, William Alexander
    Crowley, Louise E.
    Parekh, Dhruv
    Crawshaw, Anjali
    Dosanjh, Davinder P.
    Nightingale, Peter
    Thickett, David R.
    BMJ OPEN RESPIRATORY RESEARCH, 2021, 8 (01)
  • [7] Mortality and Respiratory-Related Hospitalizations in Idiopathic Pulmonary Fibrosis Not Treated With Antifibrotics
    Cottin, Vincent
    Spagnolo, Paolo
    Bonniaud, Philippe
    Nolin, Maeva
    Dalon, Faustine
    Kirchgaessler, Klaus-Uwe
    Kamath, Tripthi V.
    Van Ganse, Eric
    Belhassen, Manon
    FRONTIERS IN MEDICINE, 2021, 8
  • [8] LONG-TERM PULMONARY FUNCTION AND MORTALITY OUTCOMES IN IDIOPATHIC PULMONARY FIBROSIS PATIENTS TREATED WITH ANTIFIBROTICS
    Barnes, J.
    Harris, E.
    Matos, L.
    Harding, K.
    Thillai, M.
    THORAX, 2021, 76 : A147 - A148
  • [9] Insights into idiopathic pulmonary fibrosis in the real world
    Cottin, Vincent
    Wuyts, Wim
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46 (01) : 16 - 18
  • [10] Pirfenidone In Idiopathic Pulmonary Fibrosis In The Real World
    Song, J.
    Park, J. -H.
    Heo, E.
    Kim, D.
    Chung, H. Hee Soon
    Lee, J-K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
12345